FORCE Blog

This blog will cover topics of interest that affect our community. Unless otherwise stated, the blog articles will be written by Sue Friedman, Executive Director of FORCE.

| More

Posts Tagged ‘hereditary cancer research’

May 19, 2016

Updates in Research on Treating Hereditary Cancers

Note: This post which was originally published 08/4/15 was just updated on 05/19/16. In December 2014, the FDA approved the first targeted therapy for people with BRCA mutations. Lynparza, a type of medication known as a PARP inhibitor, was approved for women with a BRCA mutation to treat advanced ovarian, fallopian tube, or primary peritoneal cancer that has progressed after … + read more

March 30, 2016

Update on Pancreatic Cancer Genetics Research

By Talia Golan, MD and Sue Friedman, DVM BRCA and pancreatic cancer The link between breast and ovarian cancer and BRCA mutations has been known since the 1990s. However, the awareness that these mutations also increase pancreatic cancer risk is more recent. If all patients with pancreatic cancer were tested for a BRCA1 or BRCA2 … + read more

March 17, 2016

Ovarian Cancer Survivors with a Negative Genetic Test Result in the Past May Benefit from Additional Genetic Counseling/Testing

KNOW MORE is a new campaign designed by FORCE to inform every woman diagnosed with ovarian, fallopian tube, and primary peritoneal cancer about national guidelines on genetic counseling and testing for inherited gene mutations. We kicked off the campaign by launching a brief survey to better understand how women with ovarian cancer make decisions around … + read more

March 3, 2016

OlympiA: A Landmark Breast Cancer PARP Inhibitor Clinical Trial

by Sue Friedman Great progress has been made since the identification of the BRCA1 and BRCA2 genes and their link to causing breast, ovarian, pancreatic and other cancers. Over the last two decades, researchers have studied how BRCA mutations cause cancer in an effort to develop new treatments. In December 2014, Lynparza, (olaparib), a type … + read more

January 8, 2016

Value in Cancer Care: Including Consumers in the Dialogue

by Lisa Schlager, Vice President of Policy and Community Affairs Value and access to appropriate health care is of vital importance to patients and their families, particularly as cancer diagnoses continue to rise—up more than 20 percent in the past decade—and health care costs steadily increase. In this environment, more attention is being paid to … + read more

September 28, 2015

Thanks Dave Bushman, for Sharing Your Story and Supporting FORCE’s Work

  Why I fundraise: When FORCE announced its FOR OUR CHILDREN fundraising effort, I immediately signed up. Although I was extremely reluctant to ask friends and relatives to donate, I knew that many of them would respond because they know how much FORCE means to me. My wife Jessie is fundraising, too – it’s a … + read more

September 27, 2015

Beyond Awareness: Working to Improve Outcomes for People Facing Hereditary Cancer

This week we mark National Hereditary Breast and Ovarian Cancer (HBOC) Week, and on Wednesday, National Previvor Day. This awareness campaign acknowledges the over one million people and families in the United States affected by hereditary cancer, due to a BRCA, PALB2, PTEN, ATM or other mutation linked to these cancers or a strong family history … + read more

August 24, 2015

XRAYS Program Looks Behind the Headlines to Make Sense of Cancer Research

FORCE is proud to launch our new program, eXamining the Relevance of Articles for Young Survivors (XRAYS). Funded by the Centers for Disease Control (CDC), the XRAYS program was developed to meet a growing need as more and more medical research articles on breast cancer are making the headlines. With the rise of social media, more consumers are turning … + read more

April 13, 2015

Another Reason for People to Know Their BRCA Status

By sharing her BRCA status and news of her prophylactic surgeries with the world, Angelina Jolie Pitt has raised awareness about BRCA testing and hereditary cancer to new heights. Her op-eds have created the “the Angelina Effect,” a term describing how her celebrity has increased demand for these services. Still, many people who meet national … + read more

February 3, 2015

Spreading HBOC Advocacy to Japan

Last month I had the honor of giving two talks at a conference organized by the Japanese HBOC Consortium in Tokyo: one for patients and the other for health care providers. Most people in Japan have little input into their health care decisions and do not question their doctors’ recommendations. The conference organizers hoped that … + read more

June 29, 2014

FDA Approval of Promising Targeted Therapy Likely Stalled Until More Research Studies are Completed

Wednesday, June 25, 2014 was a pivotal day for our community. It began with promise and ended with disappointment. For the first time ever, a treatment targeted for BRCA-associated cancers was considered for approval by the FDA. Yesterday the FDA’s Oncologic Drug Advisory Committee (ODAC) held a hearing to consider FDA approval of the drug … + read more

March 24, 2014

Challenges to HBOC Research Enrollment: Competing Cancer Treatment Studies

Research is the key to better medical options. In prior blogs, I outlined some of the barriers to completing hereditary cancer research. This is the next blog in our series about addressing the barriers to hereditary cancer research. Hereditary cancers make up a small subset of a larger disease state. About 7% of all breast … + read more

March 3, 2014

Health Care Providers Can Help Accelerate Hereditary Cancer Research

Why HBOC research is important Hereditary cancers constitute a small subset of a larger disease state. About 7% of breast cancers and 18% of ovarian cancers are due to a BRCA mutation. The HBOC community shoulders a disproportionate cancer burden, facing lifetime cancer risks that are higher than any other known population. Our cancers tend … + read more

February 21, 2014

FORCE 15: Reasons to Join FORCEs and Attend Our 8th Annual Conference

Need a reason to attend this year’s Joining FORCEs Conference? Here are 15 good ones: It’s the largest annual gathering by and for the hereditary cancer community.  Be a part of this landmark event. We make the latest science understandable and accessible. Hear experts clearly explain the science of hereditary cancer and make the latest … + read more

February 1, 2014

Patient-Centered Outcomes Research Institute (PCORI): Research Done Differently

What is PCORI? The Patient-Centered Outcomes Research Institute (PCORI) is a new government-supported agency that approaches medical research with a focus on the patient to improve health outcomes. Aiming to answer medical questions that are most important to patients and collecting data from “real world settings,” this differs from traditional research, which typically occurs at … + read more

Connect with others.

Call our Helpline

Our helpline offers peer support for people concerned about hereditary cancer. All calls are confidential. Call any time.

Join a Local Group

FORCE has outreach groups throughout the United States and in Essex, United Kingdom that meet periodically to offer peer support, and share resources.

FORCE:Facing Our Risk of Cancer Empowered